This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Drug Names(s): abnobaVISCUM Fraxini, Mistletoe Lectin
abnobaVISCUM is mistletoe extract. The company claims that in contrast to other mistletoe products, the manufacture of abnobaVISCUM is performed using a patented pressing to produce the pressed juice in a way that ensures that the entire range of plant ingredients is transferred to the extract. The extract then contains 75% of the plant material used. Plant material from both summer and winter harvests is used, since there may be different compounds at the different times. The manufacturing process also impacts the formation of liposomes, which the company is researching further.
In general, mistletoe extracts have a long history of being investigated for treatment of cancer. They have been shown to kill cancer cells in the laboratory and to affect the immune system. For example, one class of compounds in mistletoe is lectins, which are glycoproteins binding selectively to glycoproteins or glycolipids on cell surfaces. Other components that have been studied for their usefulness in treating cancer are alkaloids, viscotoxins, and polysaccharides.
Additional information available to subscribers only: